Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000935836-25-000512
Filing Date
2025-08-14
Accepted
2025-08-14 12:34:14
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 11146
2 AGREEMENT berylex991.htm EX-99 9770
  Complete submission text file 0000935836-25-000512.txt   22620
Mailing Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453
Business Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453 781-652-4500
Checkpoint Therapeutics, Inc. (Subject) CIK: 0001651407 (see all company filings)

EIN.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89990 | Film No.: 251216435
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 225 AVENUE I STE 205 REDONDO BEACH CA 90277
Business Address 225 AVENUE I STE 205 REDONDO BEACH CA 90277 9174461561
Beryl Capital Management LLC (Filed by) CIK: 0001719307 (see all company filings)

EIN.: 474641111 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A